Arthritis, Psoriatic Clinical Trial
Official title:
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 protein subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23-mediated intracellular signaling, activation, and cytokine production. This study will consist of a screening phase (up to 6 weeks), a treatment phase (up to 48 weeks, including a placebo-controlled period from Week 0 to Week 24 and an active-controlled treatment phase from Week 24 to Week 48), and a safety follow-up phase (up to Week 60). The efficacy assessments will include assessment such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and the safety assessments will include evaluations of physical examinations, vital signs, electrocardiograms, clinical laboratory tests, and adverse events. The overall duration of the study will be up to 14 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02181673 -
A Study of Golimumab in Participants With Active Psoriatic Arthritis
|
Phase 3 | |
| Recruiting |
NCT04936308 -
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
|
Phase 3 | |
| Terminated |
NCT00090129 -
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
| Withdrawn |
NCT03625089 -
Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis
|
N/A | |
| Recruiting |
NCT05571696 -
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
|
N/A | |
| Active, not recruiting |
NCT05071664 -
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
|
Phase 2 | |
| Completed |
NCT00938015 -
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
|
N/A | |
| Suspended |
NCT03703934 -
Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls
|
||
| Recruiting |
NCT05092269 -
A Long-term Extension Study of Ustekinumab in Pediatric Participants
|
Phase 3 | |
| Terminated |
NCT05083078 -
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
|
Phase 1 | |
| Completed |
NCT02436785 -
Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening?
|
N/A | |
| Completed |
NCT02294227 -
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
|
Phase 3 | |
| Completed |
NCT00998829 -
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
|
N/A | |
| Completed |
NCT00760669 -
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
|
Phase 4 | |
| Completed |
NCT00367237 -
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
|
Phase 3 | |
| Completed |
NCT00051623 -
A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis
|
Phase 3 | |
| Withdrawn |
NCT04680676 -
A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis
|
Phase 2 | |
| Completed |
NCT03008590 -
Low Dose Naltrexone for Chronic Pain From Arthritis
|
Phase 2 | |
| Recruiting |
NCT05657847 -
Novel Complex Radiodiagnostics of Peripherial Arthropathies
|
||
| Completed |
NCT02875184 -
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
|